Inducing cell death in Glioblastoma by unknown
MEETING ABSTRACT Open Access
Inducing cell death in Glioblastoma
Shahed Tappuni*, Janis Noonan, Brona Murphy
From 4th International Conference for Healthcare and Medical Students (ICHAMS) 2014
Dublin, Ireland. 24-25 October 2014
Background
Glioblastoma is the most common primary malignant
brain tumor, and despite multimodal treatment with
surgery, radiotherapy, and temozolomide (TMZ) che-
motherapy, the prognosis is poor, with a median survival
of 16 to 19 months [1]. Therefore, alternative treatments
are necessary.
A therapy anticipated to be one of the most effective
anti- cancer treatments is tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) but resistance to
TRAIL remains a significant challenge [2].
Like TRAIL, TMZ induces apoptosis; however, unlike
TRAIL, TMZ also induces autophagy [3], which may hin-
der the apoptotic effects of the drug. Recently, the basal
level of autophagy present in cells prior to treatment has
been implicated as a potential indicator of treatment
responsiveness/resistance. To assess the basal level of
autophagy in a panel of glioblastoma cell lines in order to
determine if these levels correspond to glioblastoma
responsiveness and resistance to different treatment
strategies.
Methods
Fluorescence-activated cell sorting (FACS) and confocal
imaging were utilized to assess the basal level of autophagy
in the following GBM cells - MZ294, MZ304, MZ18,
MZ51, MZ256, MZ327, U251, U343, U373, A172 and
U87. MTT assays were utilized to measure cell viability
following differing treatment combinations. Statistical ana-
lysis was performed using unpaired student t-tests.
A p value <0.05 was considered statistically significant.
Results
FACS analysis demonstrated that the TMZ-resistant cell
lines MZ256 and MZ51 displayed the highest basal
levels of autophagy. These results were supported by the
confocal imaging experiments. The same cell lines also
demonstrated resistance to TRAIL and to the combined
treatment of TRAIL and TMZ.
Inhibition of autophagy in MZ18, MZ256, MZ51 and
MZ304 with Bafilomycin A1 (Baf-A1) sensitized these cell
lines to one or more of the treatment options. Specifically,
MZ18, MZ256 and MZ51 have responded largely with the
combination of TRAIL and Baf-A1 whereas MZ304 has
responded better with the combination of TMZ and Baf-
A1. But all of the four primary cell lines have a slightly
higher response with the combination of TRAIL, TMZ
and Baf-A1.
Conclusion
The primary GBM cell lines display higher basal levels of
autophagy than the commercial GBM cell lines, and are
more resistant to treatment. Inhibiting autophagy in such
cell lines resulted in a better response to treatment. These
findings may help in the future treatment of glioblastoma.
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